Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time
In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.
You may also be interested in...
Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.
Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.
Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.